Invitae kicks off 2015 medtech IPOs with $86m filing
This article was originally published in Clinica
After a bumper crop of medtech initial public offerings last year, the pace shows no sign of slowing. Latest to try its luck is genetic data management specialist Invitae, which has filed for a $86m IPO. The San Francisco, California company did not give any pricing details, but plans to trade on the New York Stock Exchange under the ticker symbol NVTA.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.